Progress in the Preclinical Discovery and Clinical Development of Class I and Dual Class I/IV Phosphoinositide 3-Kinase (PI3K) InhibitorsStephen J. Shuttleworth, Paul Workman|Current Medicinal Chemistry|2011Cited by 103
Functional characterization of a novel somatic oncogenic mutation of PIK3CBAndrew Whale, Stephen J. Shuttleworth|Signal Transduction and Targeted Therapy|2017Cited by 44